Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29436230 | 1.00 | MEN1 (0.59) | MEN1KMT2AASAH1CYP2D6TP53 | |
| SCHEMBL1479154 | 1.00 | MEN1 (0.59) | MEN1KMT2AASAH1CYP2D6TP53 | |
| SCHEMBL8382109 | 0.90 | MEN1 (0.71) | MEN1KMT2AASAH1CYP2D6TP53 | |
| SCHEMBL7516328 | 0.90 | MEN1 (0.71) | MEN1KMT2AASAH1CYP2D6TP53 | |
| SCHEMBL7527576 | 0.90 | MEN1 (0.71) | MEN1KMT2AASAH1CYP2D6TP53 | |
| Cedefingol SCHEMBL6593 | 0.90 | MEN1 (0.71) | MEN1KMT2AASAH1CYP2D6TP53 | |
| SCHEMBL7517337 | 0.90 | MEN1 (0.71) | MEN1KMT2AASAH1CYP2D6TP53 | |
| SCHEMBL7516917 | 0.90 | MEN1 (0.71) | MEN1KMT2AASAH1CYP2D6TP53 | |
| SCHEMBL7522091 | 0.90 | MEN1 (0.71) | MEN1KMT2AASAH1CYP2D6TP53 | |
| SCHEMBL7522023 | 0.90 | MEN1 (0.71) | MEN1KMT2AASAH1CYP2D6TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110077309-A1 | HUMECTANT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-31 | — | — | US | claimed |
| EP-4382090-A1 | COSMETICAL AND PHARMACEUTICAL COMPOSITIONS CONTAINING BACILLUS STRAINS OR FERMENTATION BROTHS THEREOF | Evonik Operations GmbH (DE) | 2024-06-12 | — | — | EP | disclosed |
| EP-3981378-A1 | COMPOSITIONS COMPRISING CERAMIDE, POLYGLYCEROL CARBOXYLIC ACID ESTER AND CHOLESTEROL | Evonik Operations GmbH (DE) | 2022-04-13 | — | — | EP | disclosed |
| US-20110077309-A1 | HUMECTANT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-03-31 | — | — | US | disclosed |
| EP-1946743-A2 | Humectant Composition | Takasago International Corporation (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-20080171794-A1 | HUMECTANT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077309-A1 | HUMECTANT COMPOSITION | HSPH1, HOGA1, HMOX2 | MEN1 3367/4885KMT2A 3617/4885ASAH1 197/4885 |
| US-20080171794-A1 | HUMECTANT COMPOSITION | HSPH1, HOGA1, HMOX2 | MEN1 3367/4885KMT2A 3617/4885ASAH1 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.